Analysts fell to the sidelines weighing in on Edwards Lifesciences (EW – Research Report) and Gilead Sciences (GILD – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Edwards Lifesciences (EW)
Evercore ISI analyst Vijay Kumar maintained a Hold rating on Edwards Lifesciences yesterday and set a price target of $89.00. The company’s shares closed last Friday at $86.43.
According to TipRanks.com, Kumar is a 3-star analyst with an average return of
Currently, the analyst consensus on Edwards Lifesciences is a Moderate Buy with an average price target of $96.24, implying a 10.6% upside from current levels. In a report released yesterday, UBS also maintained a Hold rating on the stock with a $95.00 price target.
See the top stocks recommended by analysts >>
Gilead Sciences (GILD)
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Gilead Sciences yesterday and set a price target of $78.00. The company’s shares closed last Friday at $65.42, close to its 52-week low of $65.09.
According to TipRanks.com, Flynn is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gilead Sciences with a $83.05 average price target, implying a 26.8% upside from current levels. In a report issued on April 15, Truist Financial also initiated coverage with a Hold rating on the stock with a $82.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EW:
- Edwards Lifesciences backs FY24 EPS view $2.70-$2.80, consensus $2.75
- Edwards Lifesciences sees Q2 adjusted EPS 67c-71c, consensus 70c
- Edwards Lifesciences reports Q1 adjusted EPS 66c, consensus 64c
- Edwards Lifesciences options imply 4.8% move in share price post-earnings
- Notable companies reporting after market close
